{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Chromophobe+Renal+Cell+Carcinoma",
    "query": {
      "condition": "Metastatic Chromophobe Renal Cell Carcinoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-01T21:01:11.617Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03635892",
      "title": "A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma",
        "Unclassified Renal Cell Carcinoma",
        "Papillary Renal Cell Carcinoma",
        "Fumarate Hydratase Deficient Renal Cell Carcinoma",
        "Succinate Dehydrogenase Deficient Renal Cell Carcinoma",
        "Collecting Duct Renal Cell Carcinoma",
        "Chromophobe Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2018-08-13",
      "completion_date": "2026-08",
      "has_results": false,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-09-01T21:01:11.617Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03635892"
    },
    {
      "nct_id": "NCT06805825",
      "title": "A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastrointestinal Stromal Tumors",
        "Small-cell Lung Cancer",
        "Adenoid Cystic Carcinoma",
        "Uveal Melanoma",
        "Neuroendocrine Tumors",
        "Chromophobe Renal Cell Carcinoma",
        "Clear Cell Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "NN3201",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novelty Nobility, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2025-02-03",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-09-23",
      "last_synced_at": "2026-09-01T21:01:11.617Z",
      "location_count": 5,
      "location_summary": "Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06805825"
    },
    {
      "nct_id": "NCT04623502",
      "title": "An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Kidney Cancer",
        "Renal Cell Carcinoma",
        "Clear Cell Carcinoma",
        "Urothelial Carcinoma",
        "Metastatic Kidney Cancer",
        "Metastatic Urothelial Carcinoma",
        "Papillary Renal Cell Carcinoma",
        "Chromophobe Renal Cell Carcinoma",
        "Fumarate Hydratase Deficiency",
        "Succinate Dehydrogenase-Deficient Renal Cell Carcinoma",
        "HLRCC",
        "Hereditary Leiomyomatosis and Renal Cell Cancer"
      ],
      "interventions": [
        {
          "name": "13C-Glucose",
          "type": "OTHER"
        },
        {
          "name": "13C-Acetate",
          "type": "OTHER"
        },
        {
          "name": "13C-Lactate",
          "type": "OTHER"
        },
        {
          "name": "13C-Glutamine",
          "type": "OTHER"
        },
        {
          "name": "13C-Fructose",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2019-09-30",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-09-01T21:01:11.617Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04623502"
    },
    {
      "nct_id": "NCT03145909",
      "title": "A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors Cancer"
      ],
      "interventions": [
        {
          "name": "ABBV-176",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2017-07-03",
      "completion_date": "2018-11-27",
      "has_results": false,
      "last_update_posted_date": "2018-11-29",
      "last_synced_at": "2026-09-01T21:01:11.617Z",
      "location_count": 7,
      "location_summary": "Scottsdale, Arizona • Duarte, California • New Haven, Connecticut + 4 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03145909"
    },
    {
      "nct_id": "NCT01767636",
      "title": "Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma of the Collecting Ducts of Bellini",
        "Chromophobe Renal Cell Carcinoma",
        "Kidney Medullary Carcinoma",
        "Kidney Oncocytoma",
        "Metastatic Renal Cell Cancer",
        "Papillary Renal Cell Carcinoma",
        "Recurrent Renal Cell Carcinoma",
        "Sarcomatoid Renal Cell Carcinoma",
        "Stage IV Renal Cell Cancer"
      ],
      "interventions": [
        {
          "name": "Pazopanib Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2013-05-16",
      "completion_date": "2021-01-20",
      "has_results": true,
      "last_update_posted_date": "2025-03-03",
      "last_synced_at": "2026-09-01T21:01:11.617Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01767636"
    },
    {
      "nct_id": "NCT04413123",
      "title": "Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Papillary Renal Cell Carcinoma",
        "Unclassified Renal Cell Carcinoma",
        "Translocation Renal Cell Carcinoma",
        "Chromophobe Renal Cell Carcinoma",
        "Collecting Duct Renal Cell Carcinoma",
        "Renal Cell Carcinoma",
        "Unresectable Advanced Renal Cell Carcinoma",
        "Metastatic Ncc Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bradley A. McGregor, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2020-11-05",
      "completion_date": "2027-06-20",
      "has_results": false,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-09-01T21:01:11.617Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • Dallas, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04413123"
    },
    {
      "nct_id": "NCT04071223",
      "title": "Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Renal Cell Carcinoma",
        "Chromophobe Renal Cell Carcinoma",
        "Clear Cell Renal Cell Carcinoma",
        "Collecting Duct Carcinoma",
        "Kidney Medullary Carcinoma",
        "Metastatic Malignant Neoplasm in the Bone",
        "Papillary Renal Cell Carcinoma",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Unclassified Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Radium Ra 223 Dichloride",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 134,
      "start_date": "2020-07-29",
      "completion_date": "2026-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-09-01T21:01:11.617Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Sacramento, California + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04071223"
    },
    {
      "nct_id": "NCT03541902",
      "title": "Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Neoplasms of Urinary Tract",
        "Renal Cell Carcinoma",
        "Chromophobe Renal Cell Carcinoma",
        "Metastatic Renal Cell Carcinoma",
        "Papillary Renal Cell Carcinoma",
        "Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions",
        "Sarcomatoid Renal Cell Carcinoma",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Unclassified Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib Malate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2018-05-15",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-09-01T21:01:11.617Z",
      "location_count": 3,
      "location_summary": "Houston, Texas • Sugar Land, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Sugar Land",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03541902"
    },
    {
      "nct_id": "NCT01108445",
      "title": "Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Non-clear Cell Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2010-09",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2018-01-16",
      "last_synced_at": "2026-09-01T21:01:11.617Z",
      "location_count": 9,
      "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Detroit, Michigan + 5 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01108445"
    },
    {
      "nct_id": "NCT03866382",
      "title": "Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Adenocarcinoma",
        "Bladder Clear Cell Adenocarcinoma",
        "Bladder Mixed Adenocarcinoma",
        "Bladder Neuroendocrine Carcinoma",
        "Bladder Small Cell Neuroendocrine Carcinoma",
        "Bladder Squamous Cell Carcinoma",
        "Chromophobe Renal Cell Carcinoma",
        "Collecting Duct Carcinoma",
        "Invasive Bladder Giant Cell Urothelial Carcinoma",
        "Invasive Bladder Lymphoepithelioma-Like Carcinoma",
        "Invasive Bladder Nested Urothelial Carcinoma",
        "Invasive Bladder Plasmacytoid Urothelial Carcinoma",
        "Invasive Bladder Sarcomatoid Urothelial Carcinoma",
        "Invasive Bladder Urothelial Carcinoma",
        "Kidney Medullary Carcinoma",
        "Large Cell Neuroendocrine Carcinoma",
        "Malignant Testicular Leydig Cell Tumor",
        "Malignant Testicular Sertoli Cell Tumor",
        "Metastatic Bladder Carcinoma",
        "Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma",
        "Metastatic Bladder Giant Cell Urothelial Carcinoma",
        "Metastatic Bladder Large Cell Neuroendocrine Carcinoma",
        "Metastatic Bladder Lipid-Rich Urothelial Carcinoma",
        "Metastatic Bladder Micropapillary Urothelial Carcinoma",
        "Metastatic Bladder Plasmacytoid Urothelial Carcinoma",
        "Metastatic Bladder Sarcomatoid Urothelial Carcinoma",
        "Metastatic Bladder Small Cell Neuroendocrine Carcinoma",
        "Metastatic Bladder Squamous Cell Carcinoma",
        "Metastatic Chromophobe Renal Cell Carcinoma",
        "Metastatic Kidney Medullary Carcinoma",
        "Metastatic Malignant Genitourinary System Neoplasm",
        "Metastatic Papillary Renal Cell Carcinoma",
        "Metastatic Penile Carcinoma",
        "Metastatic Prostate Small Cell Neuroendocrine Carcinoma",
        "Metastatic Sarcomatoid Renal Cell Carcinoma",
        "Metastatic Urethral Carcinoma",
        "Papillary Renal Cell Carcinoma",
        "Sarcomatoid Renal Cell Carcinoma",
        "Stage IV Bladder Cancer AJCC v8",
        "Stage IV Penile Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Stage IV Urethral Cancer AJCC v8",
        "Stage IVB Prostate Cancer AJCC v8",
        "Urachal Adenocarcinoma",
        "Urethral Clear Cell Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 314,
      "start_date": "2019-05-13",
      "completion_date": "2027-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-09-01T21:01:11.617Z",
      "location_count": 580,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 376 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03866382"
    }
  ]
}